Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why

    3 hours ago

    Goldman Sachs retained its Buy rating on Cohance Lifesciences with a target price of Rs 525, while cutting its fiscal 2027–29 earnings estimates by up to 31%.
    Click here to Read More
    Previous Article
    Mookuthi Amman 2 Box Office Collection Day 3: Nayanthara Starrer Sees 87.8% Jump, Mints This Amount
    Next Article
    Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment